AstraZeneca and Bristol-Myers Squibb Discuss Potential $400 Billion Pharmaceutical Merger

British pharmaceutical company AstraZeneca is in talks with American rival Bristol-Myers Squibb (BMS) about a possible merger, according to the Financial Times. If completed, the deal would create one of the largest pharmaceutical companies globally, valued at nearly $400 billion. Discussions have been ongoing for several months and could conclude soon, though they might also fall through.

AstraZeneca is the UK's second most valuable listed company, with a market capitalization of £196 billion ($264 billion), while Bristol-Myers Squibb is valued at approximately $133 billion. The merger would rank the combined entity as the fourth largest pharmaceutical company worldwide by market value. It would also strengthen AstraZeneca's presence in the US market, which currently accounts for nearly half of its revenue, while raising concerns in the UK about major companies relocating abroad.

AstraZeneca is listed in London and completed a New York listing in June. Neither company has commented on the reports. Previously, Pfizer attempted to acquire AstraZeneca in 2014 with a £70 billion offer, which was rejected by CEO Sir Pascal Soriot. Under his leadership, AstraZeneca has become a leading pharmaceutical firm with a strong oncology portfolio and aims to reach $80 billion in revenue by 2030, up from $58.7 billion last year.

Any merger would likely face rigorous regulatory scrutiny in both the UK and US, especially since both companies have significant cancer drug divisions that compete directly.

Summary: AstraZeneca and Bristol-Myers Squibb are negotiating a potential merger that could create a nearly $400 billion pharmaceutical giant, enhancing AstraZeneca's US market position but raising UK concerns. The deal, if finalized, would be one of the largest in the sector and subject to strict regulatory review.

Points: - AstraZeneca and Bristol-Myers Squibb are in talks for a potential $400 billion merger. - The combined company would be the fourth largest pharmaceutical firm globally by market value. - AstraZeneca aims to boost its US market presence, which accounts for nearly half its revenue. - The merger raises UK concerns about major companies leaving the country. - The deal would face intense regulatory scrutiny due to overlapping cancer drug portfolios. - Pfizer previously attempted to acquire AstraZeneca in 2014 but was rejected.

Topic: economy israel_relevant: false Entities: {"people": ["Pascal Soriot"], "organizations": ["AstraZeneca", "Bristol-Myers Squibb", "Pfizer"], "places": ["United Kingdom", "United States", "London", "New York"]}